Uncovering the Mechanism of the Xingnaojing Injection against Ischemic Stroke Using a Combined Network Pharmacology Approach and Gut Microbiota Analysis

Figure 4

Drugs-active components-target network and PPI network. (a) Drugs-active components-target network diagram of XNJ in the treatment of IS; (b) PPI network of XNJ-IS; (c) drugs-active components-target network diagram of XNJ in the treatment of IBD; (d) PPI network of XNJ-IBD. Note: (Bo) Borneolum Syntheticum, (Mo) Moschus, (Ra) Radix Curcumae, (Fr) Fructus gardenia, (Bo1) (-)-Blumealactone (C), (Mo1) Gibberellin A1, (Mo2) Gibberellin A4, (Mo3) Gibberellin A8, (Mo4) Gibberellin A17, (Mo5) Hyperin, (Mo6) trans, trans-Farnesol, (Ra1) 4-Hydroxybenzaldehyde, (Ra2) 4-Hydroxybenzoic acid, (Ra3) 6-Methyl-7-(3-oxobutyl)-bicyclo[4.1.0]heptan-3-one, (Ra4) 13-Hydroxygermacrone, (Ra5) acetic acid, (Ra6) alpha-Pinene, (Ra7) Bis(4-Hydroxybenzyl) ether, (Ra8) Curcumalactone, (Ra9) Curcumanggoside, (Ra10) Curcumenolactone (C), (Ra11) Curcumin, (Ra12) L-Asparagine, (Ra13) Oxalic acid, (Ra14) Serotonin, (Ra15) Spathulenol, (Ra16) Sucrose, (Ra17) Thymol, (Ra18) Tryptamine, (Ra19) Zederone, (Ra20) Zedoarondiol, (Ra21) Zerumin (B), (Fr1) Acetylursolic acid, (Fr2) Epijasminoside (A), (Fr3) Gardaloside, and(Fr4) Geniposide.

(a)

(b)

(c)

(d)